Emcure cuts prices of Novo’s semaglutide brand Poviztra by up to 55%
Emcure Pharmaceuticals has slashed prices of its weight management drug Poviztra, a semaglutide injection, by up to 55%, in a move aimed at expanding access to obesity treatment amid rising competition in India’s fast-growing GLP-1…
Read More...
Read More...